GoodRx Holdings Inc (GDRX)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$3.48-1.42%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
QuarterlyIQ Insights · GDRX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Chief Accounting Officer — Thomas Chan: Thomas Chan was promoted to Chief Accounting Officer.
Director — Ian T. Clark: Ian T. Clark resigned as a member of the Board of Directors.
Chief Accounting Officer — Romin Nabiey: Mr. Nabiey resigned to pursue other opportunities.
Changes in Registrant’s Certifying Accountant On March 14, 2026, the Audit and Risk Committee of the Board of Directors of GoodRx Holdings, Inc. (the “Company”), following a competitive proposal process, approved the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved the dismissal of PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm. The audit…
The filing pertains to a compensatory arrangement for an executive officer, not a management change.
Director — Dipanjan Deb: Mr. Dipanjan Deb resigned as a member of the Board of Directors, with no disagreement noted.
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
The company provided retention bonuses to the CEO and CFO.
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Co-Chairman of the Board of Directors and executive officer — Trevor Bezdek: Mr. Trevor Bezdek's employment and executive officer service ended, but he will continue as a non-employee Co-Chairman of the Board.
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Other Events On March 16, 2025 (the “Effective Date”), GoodRx Holdings, Inc. (the “Company”) entered into three Stock Purchase Agreements: (a) one with Spectrum Equity VII, L.P., Spectrum VII Investment Managers’ Fund, L.P., and Spectrum VII Co-Investment Fund, L.P. (collectively, “Spectrum”), (b) one with Francisco Partners IV, L.P. and Francisco Partners IV-A (collectively, “Francisco Partners”) and (c) one with Idea Men, LLC (“Idea Men”). Pursuant to such agreements, the Company agreed to…
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Chief Financial Officer and Treasurer — Christopher A. McGinnis: Appointment of a new Chief Financial Officer and Treasurer.
Class II director and Co-Chair of the Board — Scott Wagner: Mr. Wagner was appointed as a Class II director and Co-Chair of the Board, replacing Simon Patterson.
Chief Financial Officer — Karsten Voermann: Mr. Voermann resigned as Chief Financial Officer for personal reasons.
Chief Executive Officer and President — Wendy Barnes: Appointment of Wendy Barnes as Chief Executive Officer and President, effective January 1, 2025.
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Director — Julie Bradley: Resigned due to personal and professional commitments.
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information set forth in
Entry into a Material Definitive Agreement On July 10, 2024 (the “Effective Date”), GoodRx, Inc. (“GoodRx”), an indirect wholly-owned subsidiary of GoodRx Holdings, Inc. (the “Company”), entered into the Sixth Amendment to First Lien Credit Agreement (the “Sixth Amendment”), by and among GoodRx, as borrower, GoodRx Intermediate Holdings, LLC (“Intermediate Holdings”) and the other guarantors party thereto (collectively, together with GoodRx and Intermediate Holdings, the “Loan Parties”), Barc…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.